Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

On July 23, 2024, Nasdaq provided confirmation to the Company that for the 10 consecutive business days preceding receipt of the letter, from July 9, 2024 to July 22, 2024, the closing bid price of the ADSs was $1.00 or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed. About Chemomab Therapeutics Ltd. Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was not in compliance with the minimum bid pr ...